abstract |
Compounds of Formula I and Formula II and their pharmaceutically acceptable salts are described. The compounds of Formulas I and II are antagonists of NMDA receptor channel compliments useful for treating cerebral vascular diseases such as, for example, cerebral ischemia, cardiac arrest, stroke and Parkinson's disease. |